Organigram Global Inc.

NASDAQ:OGI

Drug Manufacturers - Specialty & Generic

Healthcare
$0.68 -1.74%

-$0.02 today

Market cap
$95.40M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $0.97High $2.24

Volume 0.62M

Average 0.67M

OGI Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Organigram Global Inc.NASDAQ: OGI

Net Income · Q2 FY2026 · quarter ended Mar 2026

Net income turns negative

Q2 FY2026 net income was -CA$923.38K, compared with CA$42.46M a year earlier. Trailing-twelve-month net income was -CA$25.23M.

Context

  • Net income amounted to 13.3% of revenue in FY2025, down 15.1 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of CA$70.73M (+385.7%) for the fiscal year ending Sep 2026, a step up from the -45.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$923.38K-104.6% QoQ
Last fiscal yearSep 2025
-CA$24.76M-45.5% YoY
LTMMar 2026
-CA$25.23M-249.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-102.2%-84.8%+17.4 pp
1 year-45.5%+385.7%+431.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CAD · from the cash flow

Latest · FY2025
(24.76M) CAD
Year-over-year change
+45.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How OGI compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -249.4% is the 8th highest of 9, against a peer median of +62.9%.
  • Net income amounts to 9.2% of revenue for OGI, versus a peer median of 25.2%.
OGI Competitors
Net Income for OGI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€340.16M EUR+84.7%+84.4%7587.8%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$151.77M USD+296.2%—8550.6%
HSDTSolana CompanyLTM Mar 2026$136.85M USD+947.5%+42.7%1427.2%
ACBAurora Cannabis Inc.LTM Mar 2026CA$58.58M CAD-507.7%-39.5%18.8%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$54.64M USD-17.6%+16.2%167.0%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$34.09M USD—-30.8%25.2%
OGIOrganigram Global Inc.LTM Mar 2026CA$25.23M CAD-249.4%—9.2%
ELMDElectromed, Inc.LTM Mar 2026$10.1M USD+41.1%+48.4%14.1%
DERMJourney Medical CorporationLTM Mar 2026$9.59M USD+15.5%-27.2%14.8%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$7.91M USD+148.0%+616.7%5.6%
Peer median (excluding OGI) —+62.9%+29.4%25.2%

Competitors are the stored peer set for OGI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(24.76M)
Depreciation & Amortization31.03M24.91M24.08M12.08M17.98M
Deferred Income Tax42.21M(88K)(2.66M)0(13.77M)
Stock-Based Compensation3.9M5.13M5.29M7.18M4.22M
Change in Working Capital24.2M(22.88M)12.51M14.96M(2.12M)
Accounts Receivables(6.01M)(24.02M)12.51M(12.06M)(15.29M)
Inventory28.68M(12.22M)000
Accounts Payables2.06M12.15M000
Other Working Capital(542K)1.21M(4.06M)27.02M13.16M
Other Non-Cash Items776K(29M)151.8M15.09M14.16M
Operating Cash Flow(28.59M)(36.21M)(35.8M)3.87M(4.3M)
Capital Expenditures(12.33M)(48.78M)(26.9M)(5.34M)(12.22M)
Acquisitions (Net)(2.54M)(11.06M)00(65.62M)
Purchases of Investments(120.02M)(15M)(7.36M)(29.24M)(1.01M)
Sales of Investments50.85M114.59M36.37M3.52M2.5M
Other Investing Activities(31.08M)4.29M31.46M(8.32M)21.8M
Investing Cash Flow(115.11M)44.03M4.56M(38.77M)(59.35M)
Debt Repayment(116.4M)(1.01M)(64.04K)(786K)(43.08K)
Common Stock Issued284.88M6.34M20K108.56M29.57M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.99M6.34M(754.15K)6K(1.29M)
Financing Cash Flow174.46M5.33M(754.15K)107.78M28.24M
Effect of Forex Changes0000(2.57M)
Net Change in Cash30.77M13.15M(68.52M)72.88M(37.98M)
Free Cash Flow(40.92M)(84.99M)(62.7M)(1.47M)(16.52M)

Organigram Global Inc.

NASDAQ:OGI

Intrinsic Alpha fair value

Locked

Current Price

$0.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.